The use of epoetin beta in anemic predialysis patients with chronic renal failure.
Two clinical studies were conducted to investigate the efficacy and safety of epoetin beta in 266 [corrected] anemic predialysis patients. Epoetin beta was administered subcutaneously either daily or thrice weekly. Mean duration of treatment was 211 days (interquartile range: 105 to 350 days).


RESULTS
Renal anemia could be corrected and the regular transfusion need could be eliminated in all patients. There was no difference in the dose requirement per week between daily and thrice weekly administration of epoetin beta. Regarding the entire study population, there was no acceleration of the progression of renal failure during epoetin beta treatment nor were there any notable changes in laboratory values other than retention values. Epoetin beta was safe and well tolerated; the most important adverse event was the development or aggravation of hypertension.
Koch
K M
KM
Medizinische Hochschule Hannover, Germany.
Koene
R A
RA
Messinger
D
D
Quarder
O
O
Scigalla
P
P
D000328:Adult; D000368:Aged; D000740:Anemia / Q000209:etiology / Q000378:metabolism / Q000628:therapy*; D001803:Blood Transfusion; D003131:Combined Modality Therapy; D003404:Creatinine / Q000378:metabolism; D018450:Disease Progression; D004311:Double-Blind Method; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D058085:Iron Compounds / Q000627:therapeutic use; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000378:metabolism / Q000628:therapy; D008297:Male; D008667:Metalloproteins / Q000378:metabolism; D008875:Middle Aged
D058085:Iron Compounds; D008667:Metalloproteins; D004921:Erythropoietin; D003404:Creatinine